CN100347184C - 可用于治疗由黄病毒科病毒如丙型肝炎及牛病毒性腹泻病毒引起的感染的双环糖类化合物 - Google Patents
可用于治疗由黄病毒科病毒如丙型肝炎及牛病毒性腹泻病毒引起的感染的双环糖类化合物 Download PDFInfo
- Publication number
- CN100347184C CN100347184C CNB2003801084682A CN200380108468A CN100347184C CN 100347184 C CN100347184 C CN 100347184C CN B2003801084682 A CNB2003801084682 A CN B2003801084682A CN 200380108468 A CN200380108468 A CN 200380108468A CN 100347184 C CN100347184 C CN 100347184C
- Authority
- CN
- China
- Prior art keywords
- compound
- application
- infection
- hepatitis
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 17
- 208000015181 infectious disease Diseases 0.000 title claims description 15
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 title abstract description 16
- -1 Bicyclic carbohydrate compounds Chemical class 0.000 title abstract description 14
- 241000710781 Flaviviridae Species 0.000 title abstract description 13
- 241000711557 Hepacivirus Species 0.000 title description 2
- 208000005176 Hepatitis C Diseases 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 64
- 239000000203 mixture Substances 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 150000001720 carbohydrates Chemical class 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 241000283690 Bos taurus Species 0.000 claims description 4
- 206010051511 Viral diarrhoea Diseases 0.000 claims description 4
- 208000004576 Flaviviridae Infections Diseases 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 208000010362 Protozoan Infections Diseases 0.000 claims 4
- 230000000144 pharmacologic effect Effects 0.000 claims 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 241000222722 Leishmania <genus> Species 0.000 claims 1
- 208000005155 Picornaviridae Infections Diseases 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000012678 infectious agent Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000002423 protozoacide Substances 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 abstract description 10
- 235000014633 carbohydrates Nutrition 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 9
- 241000710778 Pestivirus Species 0.000 abstract description 8
- 241001465754 Metazoa Species 0.000 abstract description 3
- 230000009385 viral infection Effects 0.000 abstract description 2
- 241000450599 DNA viruses Species 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 208000010710 hepatitis C virus infection Diseases 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 241001430294 unidentified retrovirus Species 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- 239000000243 solution Substances 0.000 description 29
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 27
- 241000700605 Viruses Species 0.000 description 22
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 239000011541 reaction mixture Substances 0.000 description 17
- 230000002194 synthesizing effect Effects 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 14
- 238000005160 1H NMR spectroscopy Methods 0.000 description 12
- 235000019439 ethyl acetate Nutrition 0.000 description 12
- 238000012216 screening Methods 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 11
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 10
- 230000000840 anti-viral effect Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 238000004440 column chromatography Methods 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241000700618 Vaccinia virus Species 0.000 description 7
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000701022 Cytomegalovirus Species 0.000 description 6
- 241000710831 Flavivirus Species 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000001939 inductive effect Effects 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 230000000120 cytopathologic effect Effects 0.000 description 5
- 208000006454 hepatitis Diseases 0.000 description 5
- 231100000283 hepatitis Toxicity 0.000 description 5
- 229960001866 silicon dioxide Drugs 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 241001225321 Aspergillus fumigatus Species 0.000 description 4
- 241000725619 Dengue virus Species 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 241000710886 West Nile virus Species 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- HEVMDQBCAHEHDY-UHFFFAOYSA-N (Dimethoxymethyl)benzene Chemical compound COC(OC)C1=CC=CC=C1 HEVMDQBCAHEHDY-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 201000007336 Cryptococcosis Diseases 0.000 description 3
- 241000221204 Cryptococcus neoformans Species 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 3
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 3
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 241001493065 dsRNA viruses Species 0.000 description 3
- 210000002257 embryonic structure Anatomy 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 229960000329 ribavirin Drugs 0.000 description 3
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 238000007738 vacuum evaporation Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 241001480043 Arthrodermataceae Species 0.000 description 2
- 241000714198 Caliciviridae Species 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- 241000943303 Enterococcus faecalis ATCC 29212 Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000709664 Picornaviridae Species 0.000 description 2
- 241000710924 Togaviridae Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940091771 aspergillus fumigatus Drugs 0.000 description 2
- 238000010533 azeotropic distillation Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000037304 dermatophytes Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 2
- 229940032049 enterococcus faecalis Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
- BRQIMWBIZLRLSV-UHFFFAOYSA-N 4-acetamido-3-nitrobenzoic acid Chemical compound CC(=O)NC1=CC=C(C(O)=O)C=C1[N+]([O-])=O BRQIMWBIZLRLSV-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 235000005273 Canna coccinea Nutrition 0.000 description 1
- 240000008555 Canna flaccida Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241001360526 Escherichia coli ATCC 25922 Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- DJOWTWWHMWQATC-KYHIUUMWSA-N Karpoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1(O)C(C)(C)CC(O)CC1(C)O)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C DJOWTWWHMWQATC-KYHIUUMWSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000009714 Severe Dengue Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241001045770 Trichophyton mentagrophytes Species 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 239000001083 [(2R,3R,4S,5R)-1,2,4,5-tetraacetyloxy-6-oxohexan-3-yl] acetate Substances 0.000 description 1
- MNZMECMQTYGSOI-UHFFFAOYSA-N acetic acid;hydron;bromide Chemical compound Br.CC(O)=O MNZMECMQTYGSOI-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000001716 anti-fugal effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000000656 anti-yeast Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- YNBJMIXWGPOBGE-UHFFFAOYSA-N carbanide;cyclopenta-1,3-diene;titanium(4+) Chemical compound [CH3-].[CH3-].[Ti+4].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 YNBJMIXWGPOBGE-UHFFFAOYSA-N 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- LXWYCLOUQZZDBD-LIYNQYRNSA-N csfv Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LXWYCLOUQZZDBD-LIYNQYRNSA-N 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- USPLDBATMHXKKD-UHFFFAOYSA-N dichloromethane;pentane Chemical compound ClCCl.CCCCC USPLDBATMHXKKD-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002084 enol ethers Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- SCEZYJKGDJPHQO-UHFFFAOYSA-M magnesium;methanidylbenzene;chloride Chemical compound [Mg+2].[Cl-].[CH2-]C1=CC=CC=C1 SCEZYJKGDJPHQO-UHFFFAOYSA-M 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- ANRQGKOBLBYXFM-UHFFFAOYSA-M phenylmagnesium bromide Chemical compound Br[Mg]C1=CC=CC=C1 ANRQGKOBLBYXFM-UHFFFAOYSA-M 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 108091069025 single-strand RNA Proteins 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
- C07H9/04—Cyclic acetals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Crystallography & Structural Chemistry (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43847503P | 2003-01-07 | 2003-01-07 | |
| US60/438,475 | 2003-01-07 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1751057A CN1751057A (zh) | 2006-03-22 |
| CN100347184C true CN100347184C (zh) | 2007-11-07 |
Family
ID=32713332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2003801084682A Expired - Fee Related CN100347184C (zh) | 2003-01-07 | 2003-12-22 | 可用于治疗由黄病毒科病毒如丙型肝炎及牛病毒性腹泻病毒引起的感染的双环糖类化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7125853B2 (fr) |
| EP (1) | EP1590357A4 (fr) |
| JP (2) | JP4707397B2 (fr) |
| CN (1) | CN100347184C (fr) |
| AU (1) | AU2003302275A1 (fr) |
| CA (1) | CA2512713C (fr) |
| WO (1) | WO2004062575A2 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2512713C (fr) * | 2003-01-07 | 2012-03-13 | Kemin Pharma Europe, B.V.B.A. | Composes de carbohydrates bicycliques utilises dans le traitement d'infections provoquees par les flaviviridae, tels que les virus de l'hepatite c et la diarrhee virale bovine |
| WO2004062590A2 (fr) * | 2003-01-07 | 2004-07-29 | Kemin Pharma Europe B.V.B.A. | Utilisation de glucides bicycliques en tant qu'agents bioactifs pour traiter des infections parasitaires |
| US20080182895A1 (en) * | 2006-08-25 | 2008-07-31 | Howe Anita Y M | Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto |
| WO2012056489A1 (fr) | 2010-10-25 | 2012-05-03 | トヨタ自動車株式会社 | Dispositif de commande de freins |
| CN105194204A (zh) * | 2015-09-25 | 2015-12-30 | 三穗县三人游生态养殖场 | 一种防治猪瘟的药物及其制备方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001077114A1 (fr) * | 2000-04-10 | 2001-10-18 | Merck & Co., Inc. | Inhibiteurs de la prenyl-proteine transferase |
| WO2001076694A1 (fr) * | 2000-04-10 | 2001-10-18 | Merck & Co., Inc. | Inhibiteurs de la prenyl-proteine transferase |
| US20020115861A1 (en) * | 1991-03-01 | 2002-08-22 | 3M Innovative Properties Company | Process for preparing 1-substituted, 2-substituted 1H-imidazo [4, 5-c] quinoline-4-amines |
| US20020119964A1 (en) * | 2000-08-01 | 2002-08-29 | Hansen Donald W. | Homoiminopiperidinyl hexanoic acid inhibitors of inducible nitric oxide synthase |
| WO2002096419A1 (fr) * | 2001-05-28 | 2002-12-05 | Fujisawa Pharmaceutical Co., Ltd. | Composition pharmaceutique comprenant un compose tricyclique utile pour prevenir ou traiter les dermatoses |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0524439A1 (fr) * | 1991-07-24 | 1993-01-27 | F.Hoffmann-La Roche & Co. Aktiengesellschaft | Dérivés du cyclohexane et du tétrahydropyranne et compositions antifongiques contenant ces dérivés |
| JPH06199697A (ja) * | 1992-03-06 | 1994-07-19 | Yunie:Kk | 抗ウイルス・抗菌・殺菌剤 |
| US6034073A (en) * | 1995-04-24 | 2000-03-07 | Novavax, Inc. | Solvent detergent emulsions having antiviral activity |
| JPH1072468A (ja) * | 1996-08-29 | 1998-03-17 | Rikagaku Kenkyusho | マイカラミド誘導体 |
| US6518253B1 (en) * | 1999-11-19 | 2003-02-11 | Robert Tam | Treatment of viral infections using the L-isomer of ribavirin |
| US20030199521A1 (en) * | 2001-01-13 | 2003-10-23 | Dykstra Christine C. | Compounds, methods and compositions useful for the treatment of bovine viral diarrhea virus (BVDV) infection and hepatitis C virus (HCV) infection |
| US20020052396A1 (en) * | 2001-04-23 | 2002-05-02 | Bailey Thomas R. | Compounds, compositions and methods for treating or preventing viral infections and associated diseases |
| US7138531B2 (en) * | 2001-10-15 | 2006-11-21 | Kemin Pharma B.V.B.A. | Preparation and use of carbohydrate-based bicyclic ring structures with antimicrobial and cytostatic activity |
| US7101908B2 (en) * | 2001-10-15 | 2006-09-05 | Kemin Pharma Europe B.V.B.A. | Bicyclic carbohydrate compounds useful in the treatment of infections caused by herpesviridae |
| AUPS143402A0 (en) | 2002-03-28 | 2002-05-09 | Alchemia Pty Ltd | Anomeric derivatives of monosaccharides |
| AU2002950657A0 (en) | 2002-08-08 | 2002-09-12 | Alchemia Limited | Derivatives of monosaccharides for drug discovery |
| CA2512713C (fr) * | 2003-01-07 | 2012-03-13 | Kemin Pharma Europe, B.V.B.A. | Composes de carbohydrates bicycliques utilises dans le traitement d'infections provoquees par les flaviviridae, tels que les virus de l'hepatite c et la diarrhee virale bovine |
| WO2004062590A2 (fr) * | 2003-01-07 | 2004-07-29 | Kemin Pharma Europe B.V.B.A. | Utilisation de glucides bicycliques en tant qu'agents bioactifs pour traiter des infections parasitaires |
| US7098243B2 (en) * | 2003-09-16 | 2006-08-29 | Kemin Pharma Europe B.V.B.A. | Bicyclic carbohydrates as antiviral bioactives for the treatment of infections caused by the alphaherpesvirinae HSV-1 and HSV-2 |
-
2003
- 2003-12-22 CA CA2512713A patent/CA2512713C/fr not_active Expired - Fee Related
- 2003-12-22 JP JP2004566657A patent/JP4707397B2/ja not_active Expired - Fee Related
- 2003-12-22 CN CNB2003801084682A patent/CN100347184C/zh not_active Expired - Fee Related
- 2003-12-22 AU AU2003302275A patent/AU2003302275A1/en not_active Abandoned
- 2003-12-22 US US10/743,111 patent/US7125853B2/en not_active Expired - Fee Related
- 2003-12-22 EP EP03810090A patent/EP1590357A4/fr not_active Withdrawn
- 2003-12-22 WO PCT/US2003/041720 patent/WO2004062575A2/fr active Application Filing
-
2010
- 2010-11-12 JP JP2010253627A patent/JP2011052007A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020115861A1 (en) * | 1991-03-01 | 2002-08-22 | 3M Innovative Properties Company | Process for preparing 1-substituted, 2-substituted 1H-imidazo [4, 5-c] quinoline-4-amines |
| WO2001077114A1 (fr) * | 2000-04-10 | 2001-10-18 | Merck & Co., Inc. | Inhibiteurs de la prenyl-proteine transferase |
| WO2001076694A1 (fr) * | 2000-04-10 | 2001-10-18 | Merck & Co., Inc. | Inhibiteurs de la prenyl-proteine transferase |
| US20020119964A1 (en) * | 2000-08-01 | 2002-08-29 | Hansen Donald W. | Homoiminopiperidinyl hexanoic acid inhibitors of inducible nitric oxide synthase |
| WO2002096419A1 (fr) * | 2001-05-28 | 2002-12-05 | Fujisawa Pharmaceutical Co., Ltd. | Composition pharmaceutique comprenant un compose tricyclique utile pour prevenir ou traiter les dermatoses |
Also Published As
| Publication number | Publication date |
|---|---|
| US20040209823A1 (en) | 2004-10-21 |
| WO2004062575A2 (fr) | 2004-07-29 |
| AU2003302275A8 (en) | 2004-08-10 |
| CA2512713A1 (fr) | 2004-07-29 |
| EP1590357A2 (fr) | 2005-11-02 |
| CA2512713C (fr) | 2012-03-13 |
| US7125853B2 (en) | 2006-10-24 |
| WO2004062575A3 (fr) | 2004-12-09 |
| EP1590357A4 (fr) | 2009-12-30 |
| AU2003302275A1 (en) | 2004-08-10 |
| CN1751057A (zh) | 2006-03-22 |
| JP2006514070A (ja) | 2006-04-27 |
| JP2011052007A (ja) | 2011-03-17 |
| JP4707397B2 (ja) | 2011-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1218947C (zh) | 杀菌剂三氟甲基烷氨基三唑并嘧啶及其制备方法和应用 | |
| CN1275947C (zh) | 含氮杂环羧酰胺衍生物或其盐 | |
| CN1034216C (zh) | 7-(取代)-9-[(取代甘氨酰)酰氨基]-6-脱甲基-6-脱氧四环素 | |
| CN1922181A (zh) | 通过使用咪唑并[1,2－b]哒嗪衍生物控制动物中的寄生虫 | |
| CN1382142A (zh) | 作为p38蛋白激酶的抑制剂的烷基氨基－取代的双环氮杂环类化合物 | |
| CN1026984C (zh) | 偏端霉素衍生物的制备方法 | |
| RU2013125713A (ru) | Пуринмонофосфатные пролекарства для лечения вирусных инфекций | |
| CN1325309A (zh) | 用于治疗或预防病毒感染和相关疾病的化合物、组合物和方法 | |
| CN1073437A (zh) | 药用化合物 | |
| CN100347184C (zh) | 可用于治疗由黄病毒科病毒如丙型肝炎及牛病毒性腹泻病毒引起的感染的双环糖类化合物 | |
| CN1095417A (zh) | 有机化合物的或与之有关的改进 | |
| CN1071754C (zh) | 嘧啶基吡唑衍生物 | |
| CN1057520C (zh) | N,n’－取代亚氨基二碳亚胺酸二酰胺 衍生物,含有它的药物组合物及其用途 | |
| CN1294578A (zh) | 新的萘基和酰苯胺取代的磺酰胺 | |
| CN1181818C (zh) | 治疗原虫感染的方法 | |
| CN1046334A (zh) | 新的2′-卤代亚甲基、2′-亚乙烯基和2′-乙炔基腺苷衍生物 | |
| CN1181013A (zh) | 抗病毒三氮杂化合物 | |
| CN1165301C (zh) | 组合物在制备治疗癌症的药物中的用途 | |
| CN1280279C (zh) | 双苯并异唑酮类化合物及其合成和应用 | |
| CN1220601A (zh) | 抗病毒化合物 | |
| CN1281602C (zh) | 羧酸酯类除草剂 | |
| CN105566262A (zh) | 苯并呋喃-7-烷基胺类化合物及其用途 | |
| WO2023115691A1 (fr) | Dérivé de pleuromutiline à chaîne latérale amino, son procédé de préparation et son utilisation | |
| RU2005125636A (ru) | Производные бензоксазола и их применение в качестве лигандов рецептора аденозина | |
| CN1099034A (zh) | 椭圆玫瑰树碱衍生物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071107 Termination date: 20131222 |